Capricor/CAPR

$3.84

6.37%
-
1D1W1MYTD1YMAX

About Capricor

Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of cardiosphere-derived cells (CDCs), which are mediated by secreted exosomes laden with bioactive cargo. CAP-2003 is the name of its exosomes product candidate, which is derived from its CDCs. It is also developing its exosome technology as a therapeutic platform. The Company’s focus is on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA), as well as proteins to treat or prevent a variety of diseases.
Ticker
CAPR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Linda Marban
Employees
74
Headquarters
Beverly hills, United States

Capricor Metrics

BasicAdvanced
$111.16M
Market cap
-
P/E ratio
-$1.15
EPS
3.97
Beta
-
Dividend rate

What the Analysts think about Capricor

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
388.28% upside
High $40.00
Low $8.00
$3.84
Current price
$18.75
Average price target

Capricor Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-103.27% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$6.1M
56.41%
Net income
$-6.3M
-13.7%
Profit margin
-103.27%
-44.83%

Capricor Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.79%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.31
-$0.31
-$0.29
-$0.25
-
Expected
-$0.34
-$0.32
-$0.35
-$0.29
-$0.09
Surprise
-7.46%
-3.13%
-17.14%
-13.79%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Capricor stock

Buy or sell Capricor stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing